JP2005519028A5 - - Google Patents

Download PDF

Info

Publication number
JP2005519028A5
JP2005519028A5 JP2003543594A JP2003543594A JP2005519028A5 JP 2005519028 A5 JP2005519028 A5 JP 2005519028A5 JP 2003543594 A JP2003543594 A JP 2003543594A JP 2003543594 A JP2003543594 A JP 2003543594A JP 2005519028 A5 JP2005519028 A5 JP 2005519028A5
Authority
JP
Japan
Prior art keywords
amino
adamantylmethyl
chloro
propyl
isonicotinamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003543594A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005519028A (ja
JP4559077B2 (ja
Filing date
Publication date
Priority claimed from SE0103836A external-priority patent/SE0103836D0/xx
Application filed filed Critical
Publication of JP2005519028A publication Critical patent/JP2005519028A/ja
Publication of JP2005519028A5 publication Critical patent/JP2005519028A5/ja
Application granted granted Critical
Publication of JP4559077B2 publication Critical patent/JP4559077B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003543594A 2001-11-16 2002-11-12 医薬組成物としてのn−アダマンチルメチル誘導体および中間体、ならびにそれらの製造方法 Expired - Fee Related JP4559077B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0103836A SE0103836D0 (sv) 2001-11-16 2001-11-16 Novel compounds
PCT/SE2002/002057 WO2003041707A1 (en) 2001-11-16 2002-11-12 N-adamantylmethyl derivates and intermediates as pharmaceutical compositions and processes for their preparation

Publications (3)

Publication Number Publication Date
JP2005519028A JP2005519028A (ja) 2005-06-30
JP2005519028A5 true JP2005519028A5 (https=) 2009-12-24
JP4559077B2 JP4559077B2 (ja) 2010-10-06

Family

ID=20286020

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003543594A Expired - Fee Related JP4559077B2 (ja) 2001-11-16 2002-11-12 医薬組成物としてのn−アダマンチルメチル誘導体および中間体、ならびにそれらの製造方法

Country Status (29)

Country Link
US (1) US7129246B2 (https=)
EP (1) EP1448195B1 (https=)
JP (1) JP4559077B2 (https=)
KR (1) KR20040058290A (https=)
CN (1) CN1585640B (https=)
AR (1) AR037534A1 (https=)
AT (1) ATE344034T1 (https=)
AU (1) AU2002347741B2 (https=)
BR (1) BR0214142A (https=)
CA (1) CA2464863A1 (https=)
CO (1) CO5580747A2 (https=)
DE (1) DE60215851T2 (https=)
DK (1) DK1448195T3 (https=)
ES (1) ES2274110T3 (https=)
HU (1) HUP0402560A3 (https=)
IL (1) IL161693A0 (https=)
IS (1) IS7261A (https=)
MX (1) MXPA04004498A (https=)
MY (1) MY136430A (https=)
NO (1) NO20042155L (https=)
NZ (1) NZ532755A (https=)
PL (1) PL370855A1 (https=)
PT (1) PT1448195E (https=)
RU (1) RU2300525C2 (https=)
SE (1) SE0103836D0 (https=)
TW (1) TW200407297A (https=)
UA (1) UA77978C2 (https=)
WO (1) WO2003041707A1 (https=)
ZA (1) ZA200403682B (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
GB0013737D0 (en) 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
SE0300480D0 (sv) * 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
WO2004105797A1 (en) * 2003-05-29 2004-12-09 Astrazeneca Ab A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
MXPA05012705A (es) * 2003-05-29 2006-02-08 Astrazeneca Ab Una composicion farmaceutica que comprende un antagonista del receptor p2x7 y un factor alfa de necrosis tumoral.
US20070281931A1 (en) * 2003-05-29 2007-12-06 Nigel Boughton-Smith Pharmaceutical Composition Containing a P2x7 Receptor Antagonist and Methotrexate
GB0312609D0 (en) * 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
KR100554155B1 (ko) * 2003-06-09 2006-02-22 학교법인 포항공과대학교 금속/반도체 나노막대 이종구조를 이용한 전극 구조물 및그 제조 방법
SE0302139D0 (sv) * 2003-07-28 2003-07-28 Astrazeneca Ab Novel compounds
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
SE0302488D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab New combination
SA05260265A (ar) * 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
SE0402925D0 (sv) * 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds
EP2591675A1 (en) 2006-11-27 2013-05-15 H. Lundbeck A/S Heteroaryl amide derivatives
CA2680761A1 (en) * 2007-03-22 2008-09-25 Astrazeneca Ab Quinoline derivatives for the treatment of inflammatory diseases
WO2008124153A1 (en) 2007-04-10 2008-10-16 H. Lundbeck A/S Heteroaryl amide analogues as p2x7 antagonists
PE20091036A1 (es) 2007-11-30 2009-08-15 Astrazeneca Ab Derivado de quinolina como antagonista del receptor p2x7
BRPI0910034B1 (pt) 2008-03-25 2022-02-08 Affectis Pharmaceuticals Ag Antagonistas do p2x7r e composições farmacêuticas que os compreendem
AU2010237302A1 (en) 2009-04-14 2011-12-01 Affectis Pharmaceuticals Ag Novel P2X7R antagonists and their use
SG185400A1 (en) 2010-05-14 2012-12-28 Affectis Pharmaceuticals Ag Novel methods for the preparation of p2x7r antagonists
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
CN103687860B (zh) 2011-07-22 2016-06-08 埃科特莱茵药品有限公司 作为p2x7受体拮抗剂的杂环酰胺衍生物
US9409917B2 (en) 2012-01-20 2016-08-09 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists
KR101576235B1 (ko) 2012-11-30 2015-12-11 한국생명공학연구원 신규한 이치환 아다만틸 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 암 전이 억제용 약학적 조성물
WO2014091415A1 (en) 2012-12-12 2014-06-19 Actelion Pharmaceuticals Ltd Indole carboxamide derivatives as p2x7 receptor antagonists
KR102232744B1 (ko) 2012-12-18 2021-03-26 이도르시아 파마슈티컬스 리미티드 P2x7 수용체 길항제로서의 인돌 카르복사미드 유도체
ES2616883T3 (es) 2013-01-22 2017-06-14 Actelion Pharmaceuticals Ltd. Derivados amida heterocíclicos como antagonistas del receptor P2X7
CA2896790C (en) 2013-01-22 2022-05-10 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists
CN104163795B (zh) * 2014-08-19 2016-02-03 四川大学 盐酸烟酰美金刚胺溶剂合物、其制备方法和用途
CN104693084B (zh) * 2015-02-12 2016-03-16 佛山市赛维斯医药科技有限公司 含腈基苯基的n-金刚烷酰胺类化合物、其制备方法及用途
CN104628615B (zh) * 2015-02-12 2016-04-06 佛山市赛维斯医药科技有限公司 含卤代苯的n-金刚烷酰胺类化合物、其制备方法及其用途
CN104628616B (zh) * 2015-02-12 2016-06-01 佛山市赛维斯医药科技有限公司 含对硝基苯基的n-金刚烷酰胺类化合物、其制备方法及用途
CN104628617B (zh) * 2015-02-12 2016-04-06 佛山市赛维斯医药科技有限公司 N-金刚烷酰胺类葡萄糖激酶活化剂、制备方法及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3352912A (en) 1963-07-24 1967-11-14 Du Pont Adamantanes and tricyclo[4. 3. 1. 1 3.8] undecanes
US3471491A (en) * 1967-08-28 1969-10-07 Squibb & Sons Inc Adamantyl-s-triazines
US3464998A (en) * 1968-03-04 1969-09-02 Searle & Co Adamantyl esters and amides of pyridinecarboxylic acids
GB1274652A (en) 1968-08-27 1972-05-17 Lilly Industries Ltd Adamantanyl-alkylamine derivatives and their preparation
US4027035A (en) * 1968-08-27 1977-05-31 Eli Lilly And Company Therapeutic uses of adamantanealkylamine compounds
IL53441A0 (en) 1977-11-22 1978-01-31 Teva Pharma Methyladamantyl hydrazines their preparation and pharmaceutical compositions containing them
US4751292A (en) * 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
WO1990010622A1 (fr) * 1989-03-10 1990-09-20 Idemitsu Kosan Co. Ltd. Derives de pyridine et leurs sels, et agent insecticide/acaricide les contenant en tant qu'ingredient actif
CA2167154A1 (en) 1993-08-10 1995-02-16 Sarkis Barret Kalindjian Gastrin and cck receptor ligands
US6034136A (en) * 1997-03-20 2000-03-07 Novartis Ag Certain cyclic thio substituted acylaminoacid amide derivatives
FR2761358B1 (fr) 1997-03-27 1999-05-07 Adir Nouveaux composes de n-aryl piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704544D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
CZ20013608A3 (cs) 1999-04-09 2002-05-15 Astrazeneca Ab Adamantanové deriváty
GB0013737D0 (en) 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
SE0200920D0 (sv) 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds

Similar Documents

Publication Publication Date Title
JP2005519028A5 (https=)
JP4559077B2 (ja) 医薬組成物としてのn−アダマンチルメチル誘導体および中間体、ならびにそれらの製造方法
US6043284A (en) Anti-atherosclerotic diaryl compounds
DE60036968T2 (de) Adamantanderivate zur Behandlung von entzündlichen, immunologischen und kardiovaskulären Erkrankungen
AU2002347741A1 (en) N-adamantylmethyl derivates and intermediates as pharmaceutical compositions and processes for their preparation
US4226878A (en) Imidazole derivative
TWI254038B (en) N-phenpropylcyclopentyl-substituted glutaramide derivatives as NEP inhibitors for FSAD
KR20100132073A (ko) Pai―1 저해제
JP2004506611A5 (https=)
JP2722250B2 (ja) 新規なジアミン化合物及びこれを含有する脳機能障害改善剤
JP3179599B2 (ja) 縮合ベンゼンオキシ酢酸誘導体およびそれらを有効成分として含有する薬剤
US20240400532A1 (en) Nitric oxide releasing prodrugs of mda and mdma
JP2015516968A5 (https=)
JPH04507421A (ja) 5―(1―アミノシクロヘキシル)―2(1h)―ピリジノン及び関連化合物
NZ201479A (en) N-phenethyl-alpha,omega-alkylenediamines and pharmaceutical compositions
CA3214066A1 (en) 1,3-substituted cyclobutyl derivatives and uses thereof
JP2001240581A (ja) アミノベンズアミド誘導体およびその用途
KR20010101818A (ko) (1-페나시-3-페닐-3-피페리딜에틸)피페리딘 유도체, 그의제조 방법 및 이를 함유하는 제약 조성물
JPH07165681A (ja) 1,3−ベンゼンジメタンアミン誘導体
JP2024102016A (ja) 複素環化合物の医薬用途
JP2024525719A (ja) 複素環化合物
BR122025005591B1 (pt) Uso de e processo para preparação de derivados de ciclobutila 1,3- substituída, combinação farmacêutica, e kit
EA050893B1 (ru) Производные 1,3-замещенного циклобутила и способы их применения
BR122025005591A2 (pt) Uso de e processo para preparação de derivados de ciclobutila 1,3-substituída, combinação farmacêutica, e kit
BR112023019496B1 (pt) Derivados de ciclobutila 1,3-substituída, e composição farmacêutica